InCarda Therapeutics Announces Abstract Acceptances for the Heart Rhythm 2017 Conference
San Francisco, California, March 14, 2017 – InCarda Therapeutics, Inc. (InCarda), a privately held biopharmaceutical company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the acceptance of two abstracts for poster presentations at the Heart Rhythm Society’s 38th Annual Scientific Sessions (HRS) to be held in Chicago, IL from May 10 – 13, 2017.
The abstracts are:
Rapid Cardioversion of Acute-Onset Atrial Fibrillation with Pulmonary Delivery of Flecainide in Anesthetized Dogs; Authored by Luiz Belardinelli, M.D., and colleagues of InCarda Therapeutics.
Accelerated Conversion of Atrial Fibrillation to Sinus Rhythm by Intratracheal Delivery of Flecainide Acetate in a Porcine Model; Authored by Richard L. Verrier, Ph.D., and colleagues of Beth Israel Deaconess Medical Center, Harvard Medical School.
Dr. Verrier is a well-known expert in preclinical models of cardiac arrhythmia. He is also collaborating on InCarda’s clinical research program.
“As we continue to advance the clinical development of InRhythm™ (inhaled flecainide) for acute cardioversion of recent onset atrial fibrillation (AF) in patients with paroxysmal atrial fibrillation, we are increasingly optimistic about the future of this exciting product candidate,” stated Luiz Belardinelli, M.D., chief medical officer of InCarda. “We believe that by delivery of flecainide via inhalation, we can develop a safe and effective product. We are looking forward to presenting our results at the HRS as well as at future medical conferences.”
InCarda’s Lead Product for PAF
Paroxysmal atrial fibrillation (PAF), the most common type of cardiac arrhythmia (abnormal heart rhythm) is characterized by rapid and irregular heartbeats that often lead to palpitations and other disabling symptoms (e.g., fatigue). Orally administered flecainide is a commonly prescribed antiarrhythmic drug. InCarda is evaluating an inhaled formulation of this drug to treat symptomatic recent onset AF. Inhaled delivery through the lung and pulmonary vein directly to the heart offers the potential for faster conversion of PAF to sinus rhythm with rapid relief of symptoms associated with PAF, both in and out-ofhospital,
along with enhanced safety.
About InCarda (www.incardatherapeutics.com)
InCarda Therapeutics, located in the San Francisco Bay Area with operations in Australia, is focused on transforming cardiovascular disease treatment through pulmonary drug delivery of established drugs. The company is led by a team with extensive experience in drug development and inhalation delivery. The lead product under development is a clinical-stage inhaled therapy intended to treat recent onset AF in patients with paroxysmal atrial fibrillation (PAF). InCarda is also working on additional research concepts that leverage the same platform technology to target the heart for acute cardiac conditions.